CETUXIMAB SAROTALOCAN SODIUM

UNII:	MG94W1I5XW
Formula:
Preferred Substance Name:	CETUXIMAB SAROTALOCAN SODIUM
GSRS Full Record:	MG94W1I5XW i

2166339-33-7
ASP-1929
CETUXIMAB SAROTALOCAN SODIUM [JAN]
CETUXIMAB SAROTALOCAN SODIUM [WHO-DD]
CETUXIMAB-IRDYE 700DX CONJUGATE
IMMUNOGLOBULIN G1, ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR) (HUMAN-MOUSE MONOCLONAL C225 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL C225 .KAPPA.-CHAIN, DIMER, AMIDE WITH SODIUM (OC-6-13)-(6-(((3-((29H,31H-PHTHALOCYANIN-1-YL-.KAPPA.N29,.KAPPA.N30,.KAPPA.N31,.KAPPA.N32)OXY)PROPOXY)CARBONYL)AMINO)HEXANOATO(2-))BIS(N-(3-((HYDROXY-.KAPPA.O)DIMETHYLSILYL)PROPYL)-3-SULFO-N,N-BIS(3-SULFOPROPYL)-1-PROPANAMINIUMATO(4-))SILICATE(4-) (4:1)
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR, AVIAN ERYTHROBLASTIC LEUKEMIA VIRAL (V-ERB-B) ONCOGENE HOMOLOG, ERBB)), CHIMERIC MONOCLONAL ANTIBODY CONJUGATED TO IRDYE 700DX (IR700) NEAR-INFRARED PHOTOSENSITIZING DYEGAMMA1 HEAVY CHAIN CHIMERIC (1-449) (VH (MUS MUSCULUS IGHV2-2*03 (93.8%)-(IGHD)-IGHJ3*01 (100%)) (8.7.13) (1-119)-HOMO SAPIENS IGHG1*03 (100%), G1M3, NG1M1 (CH1 R120 (216) (120-217), HINGE (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)), (222-214')-DISULFIDE WITH KAPPA LIGHT CHAIN CHIMERIC (1'-214') (V-KAPPA (MUS MUSCULUS IGKV5-48*01 (95.8%)-IGKJ5*01 (100%)) (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214'))DIMER (228-228'':231-231'')-BISDISULFIDECONJUGATED ON AN AVERAGE OF 2 OR 3 LYSYL TO PHOTOSENSITIZING DYE IRDYE 700DX
RM-1929

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

CETUXIMAB SAROTALOCAN SODIUM

Synonyms and Mappings

Resources